慢性活动性EB病毒感染临床诊断与治疗进展

周哲; 邵凌云; 张文宏

doi:10.13201/j.issn.1004-2806.2022.01.003

慢性活动性EB病毒感染临床诊断与治疗进展

- 复旦大学附属华山医院感染科(上海，200040)

详细信息

作者简介:
专家简介：邵凌云，复旦大学附属华山医院感染科副主任、主任医师、博士生导师。曾作为访问学者至美国伊利诺大学芝加哥分校微生物与免疫学系进行课题研究。现任上海市医学会感染病学分会副主任委员，上海市医师协会感染科医师分会副会长，上海市医学会感染病学分会细菌与真菌学组组长，上海市微生物学会医学微生物学专委会副主任委员，上海市医学会结核病学分会委员，上海市免疫学会感染免疫专委会委员。致力于感染性疾病，包括EBV感染相关疾病的临床和相关研究工作

通讯作者: 邵凌云，E-mail：lingyun26@fudan.edu.cn

中图分类号: R511

收稿日期: 2021-11-29

刊出日期: 2022-01-01

Progress in clinical diagnosis and treatment of chronic active Epstein-Barr virus infection

More Information

Corresponding author: SHAO Lingyun, E-mail: lingyun26@fudan.edu.cn

Received Date: 29 November 2021

Publish Date: 01 January 2022

摘要

- 慢性活动性EB病毒感染 /
- 诊断 /
- 治疗
- chronic active EBV infection /
- diagnosis /
- treatment

HTML全文

表 1 CAEBV的三步疗法^[21]

步骤	方案
第一步	目的：抑制活化的T、NK和巨噬细胞方案：泼尼松龙0.5~2 mg/(kg·d)×7 d/周依托泊苷150 mg/m²×1 d/周环孢素3 mg/kg×2/d×7 d/周
第二步	目的：尽可能消除EBV感染的T/NK细胞一线方案：改良CHOP方案长春新碱1.5 mg/m² 环磷酰胺750 mg/m² 吡柔比星25 mg/(m²·d)×2 d 泼尼松龙50 mg/(m²·d)×5 d 二线方案：ESCAP方案依托泊苷150 mg/m² 阿糖胞苷1.5 g/m²×8次左旋天冬酰胺酶6000 U/(m²·d)×5 d 甲泼尼龙62.5 mg/m²×2/d 泼尼松龙30 mg/(m²·d)×4 d
第三步	HSCT

下载: 导出CSV

参考文献(33)

[1]	Kawamoto K, Miyoshi H, Suzuki T, et al. A distinct subtype of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder: adult patients with chronic active Epstein-Barr virus infection-like features[J]. Haematologica, 2018, 103(6): 1018-1028. doi: 10.3324/haematol.2017.174177
[2]	Nowalk A, Green M. Epstein-Barr Virus[J]. Microbiol Spectr, 2016, 4(3). doi:10.1128/microbiolspec.DMIH2-0011-2015.
[3]	Taylor GS, Long HM, Brooks JM, et al. The immunology of Epstein-Barr virus-induced disease[J]. Annu Rev Immunol, 2015, 33: 787-821. doi: 10.1146/annurev-immunol-032414-112326
[4]	Kimura H, Cohen JI. Chronic Active Epstein-Barr Virus Disease[J]. Front Immunol, 2017, 8: 1867. doi: 10.3389/fimmu.2017.01867
[5]	Jiang L, Gu ZH, Yan ZX, et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma[J]. Nat Genet, 2015, 47(9): 1061-1066. doi: 10.1038/ng.3358
[6]	Jones JF, Shurin S, Abramowsky C, et al. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections[J]. N Engl J Med, 1988, 318(12): 733-741. doi: 10.1056/NEJM198803243181203
[7]	Okano M, Kawa K, Kimura H, et al. Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection[J]. Am J Hematol, 2005, 80(1): 64-69. doi: 10.1002/ajh.20398
[8]	杨小舟, 杨清銮, 陈宇明, 等. 成人EB病毒感染相关性疾病的临床特征及预后分析[J]. 中华传染病杂志, 2021, 39(3): 163-167.
[9]	Kimura H, Ito Y, Kawabe S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases[J]. Blood, 2012, 119(3): 673-686. doi: 10.1182/blood-2011-10-381921
[10]	Collins PJ, Fox CP, George L, et al. Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells[J]. Blood, 2021, 137(2): 203-215. doi: 10.1182/blood.2020005611
[11]	Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375-2390. doi: 10.1182/blood-2016-01-643569
[12]	Yonese I, Sakashita C, Imadome KI, et al. Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification[J]. Blood Adv, 2020, 4(13): 2918-2926. doi: 10.1182/bloodadvances.2020001451
[13]	Fryer JF, Heath AB, Wilkinson DE, et al. A collaborative study to establish the 1st WHO International Standard for Epstein-Barr virus for nucleic acid amplification techniques[J]. Biologicals, 2016, 44(5): 423-433. doi: 10.1016/j.biologicals.2016.04.010
[14]	Yu S, Yang Q, Wu J, et al. Clinical application of Epstein-Barr virus DNA loads in Epstein-Barr virus-associated diseases: A cohort study[J]. J Infect, 2021, 82(1): 105-111. doi: 10.1016/j.jinf.2020.11.027
[15]	Fournier B, Boutboul D, Bruneau J, et al. Rapid identification and characterization of infected cells in blood during chronic active Epstein-Barr virus infection[J]. J Exp Med, 2020, 217(11): e20192262. doi: 10.1084/jem.20192262
[16]	Ghosh S, Köstel Bal S, Edwards ESJ, et al. Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency[J]. Blood, 2020, 136(23): 2638-2655. doi: 10.1182/blood.2020006738
[17]	Kawa K, Sawada A, Sato M, et al. Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection[J]. Bone Marrow Transplant, 2011, 46(1): 77-83. doi: 10.1038/bmt.2010.122
[18]	Dojcinov SD, Fend F, Quintanilla-Martinez L. EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts[J]. Pathogens, 2018, 7(1): 28. doi: 10.3390/pathogens7010028
[19]	Arai A. Chronic Active Epstein-Barr Virus Infection: The Elucidation of the Pathophysiology and the Development of Therapeutic Methods[J]. Microorganisms, 2021, 9(1): 180. doi: 10.3390/microorganisms9010180
[20]	Sawada A, Inoue M. Hematopoietic Stem Cell Transplantation for the Treatment of Epstein-Barr Virus-Associated T- or NK-Cell Lymphoproliferative Diseases and Associated Disorders[J]. Front Pediatr, 2018, 6: 334. doi: 10.3389/fped.2018.00334
[21]	Sawada A, Inoue M, Kawa K. How we treat chronic active Epstein-Barr virus infection[J]. Int J Hematol, 2017, 105(4): 406-418. doi: 10.1007/s12185-017-2192-6
[22]	Bollard CM, Cohen JI. How I treat T-cell chronic active Epstein-Barr virus disease[J]. Blood, 2018, 131(26): 2899-2905. doi: 10.1182/blood-2018-03-785931
[23]	Cohen JI, Jaffe ES, Dale JK, et al. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States[J]. Blood, 2011, 117(22): 5835-5849. doi: 10.1182/blood-2010-11-316745
[24]	Savoldo B, Huls MH, Liu Z, et al. Autologous Epstein-Barr virus(EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection[J]. Blood, 2002, 100(12): 4059-4066. doi: 10.1182/blood-2002-01-0039
[25]	Onozawa E, Shibayama H, Takada H, et al. STAT3 is constitutively activated in chronic active Epstein-Barr virus infection and can be a therapeutic target[J]. Oncotarget, 2018, 9(57): 31077-31089. doi: 10.18632/oncotarget.25780
[26]	Albeituni S, Verbist KC, Tedrick PE, et al. Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis[J]. Blood, 2019, 134(2): 147-159. doi: 10.1182/blood.2019000761
[27]	Jin Z, Wang Y, Wang J, et al. Long-term survival benefit of ruxolitinib in a patient with relapsed refractory chronic active Epstein-Barr virus[J]. Ann Hematol, 2019, 98(8): 2003-2004. doi: 10.1007/s00277-019-03647-5
[28]	Song Y, Wang J, Wang Y, et al. Ruxolitinib in Patients With Chronic Active Epstein-Barr Virus Infection: A Retrospective, Single-Center Study[J]. Front Pharmacol, 2021, 12: 710400. doi: 10.3389/fphar.2021.710400
[29]	Bi XW, Wang H, Zhang WW, et al. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma[J]. J Hematol Oncol, 2016, 9(1): 109. doi: 10.1186/s13045-016-0341-7
[30]	Kwong YL, Chan TSY, Tan D, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase[J]. Blood, 2017, 129(17): 2437-2442. doi: 10.1182/blood-2016-12-756841
[31]	Liu P, Pan X, Chen C, et al. Nivolumab treatment of relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults[J]. Blood, 2020, 135(11): 826-833. doi: 10.1182/blood.2019003886
[32]	Kanazawa T, Hiramatsu Y, Iwata S, et al. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases[J]. Clin Cancer Res, 2014, 20(19): 5075-5084. doi: 10.1158/1078-0432.CCR-14-0580
[33]	Xue W, Zhang M. Updating targets for natural killer/T-cell lymphoma immunotherapy[J]. Cancer Biol Med, 2021, 18(1): 52-62. doi: 10.20892/j.issn.2095-3941.2020.0400